Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus PREDNICARBATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus PREDNICARBATE.
ENSTILAR vs PREDNICARBATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Prednicarbate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
Topical: apply sparingly to affected area twice daily; maximum 50 g per week.
None Documented
None Documented
Clinical Note
moderatePrednicarbate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Gatifloxacin."
Clinical Note
moderatePrednicarbate + Rosoxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Rosoxacin."
Clinical Note
moderatePrednicarbate + Levofloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin."
Clinical Note
moderateCalcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life: approximately 1-2 hours; clinical context: short half-life supports topical use with minimal systemic accumulation
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Primarily renal (<2% unchanged) and fecal (biliary excretion of metabolites)
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid
Prednicarbate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Trovafloxacin."